跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
柯 文謙
教授
內科學科
https://orcid.org/0000-0001-7497-149X
電子郵件
winston
mail.ncku.edu
tw
h-index
27345
引文
67
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1995 …
2025
每年研究成果
概覽
指紋
網路
專案
(27)
研究成果
(666)
類似的個人檔案
(12)
監製作品
(3)
指紋
查看啟用 Wen-Chien Ko 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Infection
9%
Abscess
8%
Acinetobacter Baumannii
17%
Aeromonas
12%
Antibiotic Therapy
10%
Antibiotics
15%
Antiinfective Agent
48%
Antimicrobial Resistance
27%
Antimicrobial Therapy
18%
Bloodstream Infection
100%
Carbapenem
25%
Carbapenem Derivative
11%
Carbapenemase
7%
Cefepime
9%
Cefotaxime
9%
Ceftriaxone
7%
Ciprofloxacin
8%
Clostridium Difficile Infection
9%
Cohort Study
7%
Colistimethate
6%
Coronavirinae
11%
Dengue
12%
Diseases
33%
Enterobacteriaceae
21%
Escherichia coli
25%
Extended Spectrum Beta Lactamase
23%
Gram Negative Bacterium
8%
HIV
13%
Imipenem
10%
Infection
59%
Infectious Agent
18%
Klebsiella pneumoniae
29%
Levofloxacin
8%
Meropenem
8%
Methicillin-Resistant Staphylococcus Aureus
8%
Minimum Inhibitory Concentration
12%
Minocycline
7%
Mortality Rate
16%
Pandemic
9%
Penicillinase
31%
Prevalence
8%
Prospective Study
6%
Pseudomonas aeruginosa
13%
Quinolone Derivative
13%
Retrospective Study
6%
Salmonella
15%
Sepsis
7%
Streptococcus pneumonia
7%
Tigecycline
12%
Vancomycin-Resistant Enterococcus
6%
Medicine and Dentistry
Abdominal Infection
5%
Abscess
5%
Aeromonas
5%
Antibiotic Resistance
16%
Antibiotic Therapy
6%
Antiinfective Agent
20%
Antimicrobial Therapy
17%
Avibactam Plus Ceftazidime
6%
Bloodstream Infection
54%
Carbapenem
16%
Carbapenem Derivative
5%
Clostridium Difficile Infection
7%
Cohort Analysis
7%
COVID-19
14%
Dengue Fever
5%
Diseases
7%
Emergency Department
10%
Enterobacteriaceae
10%
Escherichia coli
14%
Extended Spectrum Beta Lactamase
15%
Gram-Negative Bacteria
5%
Human immunodeficiency virus
14%
In Vitro
9%
Infection
35%
Intensive Care Unit
8%
Klebsiella pneumoniae
22%
Meropenem
5%
Mortality Rate
12%
Odds Ratio
17%
Pathogen
12%
Penicillinase
15%
Peptoclostridium difficile
6%
Prevalence
5%
Pseudomonas aeruginosa
7%
Q Fever
5%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Keyphrases
30-day Mortality
5%
Adjusted Odds Ratio
9%
Aeromonas
5%
Antimicrobial
11%
Antimicrobial Evaluation
5%
Antimicrobial Resistance
8%
Antimicrobial Resistance Surveillance
5%
Bacteremia
24%
Bloodstream Infection
9%
Carbapenems
9%
Cefepime
9%
Clinical Impact
7%
Clostridioides Difficile
6%
Clostridium Difficile Infection
10%
Community-onset
7%
Confidence Interval
5%
Emergency Department
8%
Enterobacteriaceae Bacteraemia
5%
Hospital-acquired Bacteraemia
8%
Klebsiella Pneumoniae (K. pneumoniae)
12%
Klebsiella Pneumoniae Carbapenemase
6%
Minimum Inhibitory Concentration
6%
Monomicrobial
7%
Non-susceptible
7%
Risk Factors
8%
Soft Tissue Infection
5%
Southern Taiwan
15%
Taiwan
31%
Third-generation Cephalosporins
5%
Tigecycline
5%
Vibrio Vulnificus
5%
